Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
List view / Grid view
News
Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
Roche announces phase II clinical results of crenezumab in Alzheimer’s disease
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
Pfizer to Acquire InnoPharma, Inc.
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
Mundipharma EDO GmbH shows strong preclinical activity with its lead compound (EDO-S101) in Multiple Myeloma
15 July 2014 | By Mundipharma EDO GmbH
Mundipharma EDO GmbH is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDO-S101...
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
Domainex reports success of its lead compound in pre-clinical model of COPD and secures £1.4m Biomedical Catalyst Award
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
Fraunhofer IME integrates European ScreeningPort to enhance its expertise and capabilities in drug discovery
9 July 2014 | By Fraunhofer IME
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
DaVita Labs and Myriad RBM announce biomarker research collaboration
7 July 2014 | By Myriad RBM
Collaboration will focus on development of novel diagnostic tests for dialysis patients...
Drug Discovery Conversations: Brian Pollok, Entrepreneur-in-Residence, University of Virginia
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
Actavis completes acquisition of Furiex Pharmaceuticals
3 July 2014 | By Actavis
Actavis plc announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc...
Roche announces definitive agreement to acquire Seragon Pharmaceuticals
2 July 2014 | By Roche
Roche announced that Genentech has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California, USA...
Taiho Oncology, Inc. announces results from TAS-102 global Phase III RECOURSE trial in refractory metastatic colorectal cancer
30 June 2014 | By Taiho Oncology
Taiho Oncology, Inc. announced detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug...